CAN-3110 by Candel Therapeutics for High-Grade Glioma: Likelihood of Approval
CAN-3110 is under clinical development by Candel Therapeutics and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase…
CAN-3110 is under clinical development by Candel Therapeutics and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase…
LP-184 is under clinical development by Starlight Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to…
ICTCAR-028 is under clinical development by Innovative Cellular Therapeutics and currently in Phase III for Hematological Tumor. According to GlobalData,…
Dalfampridine IR is under clinical development by Solaxa and currently in Phase II for Spinocerebellar Ataxia (SCA). According to GlobalData,…
NN-6561 is under clinical development by Novo Nordisk and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to…
AZD-2389 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData,…
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Homozygous Familial Hypercholesterolemia (HoFH). According to…
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Heterozygous familial hypercholesterolemia (heFH). According to…
BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Metastatic Ovarian Cancer. According to…
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Hypertriglyceridemia. According to GlobalData, Phase II…